RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Repetitive Transcranial Magnetic Stimulation for Multiple Sclerosis

Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.

Official registry: https://clinicaltrials.gov/study/NCT07159789 · Clinique Neuro-Outaouais · enrollment listed as 70

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Repetitive Transcranial Magnetic Stimulation. The registry lists allocation as randomized. Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.

They plan to enroll about 70 people at Gatineau. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

Non-Invasive Neuromodulation in MS Induced Spastic Paraparesis

Interventions: Repetitive Transcranial Magnetic Stimulation

Primary outcome (registry wording): Improvement of T25FWT (Timed 25-Foot Walk Test)

Who it is for (from inclusion criteria)

Ages 18 Years to 70 Years
Age ≥ 18 years and less than 71 years
Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018)
EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more
Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening
No change in disease modifying therapy for at least 3 months prior to screening
Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol

Who the registry excludes

Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study
Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation
Pregnant or breastfeeding or intending to become pregnant during the study
Any previous rTMS therapy for any indication
Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker
Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study

Public study contact (from the registry)

Francois Jacques, Neurologist

819-777-2500

francois.jacques@neuro-outaouais.ca

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Clinique Neuro-Outaouais — Gatineau, Quebec, Canada (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System

Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS).

NCT00794352 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

RecruitingPhase 1 / Phase 2Boston, Massachusetts

Phase 1 / Phase 2: testing [F-18]PBR06 for Multiple Sclerosis

The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.

NCT02649985 · Official ClinicalTrials.gov record · Brigham and Women's Hospital

RecruitingPhase 3Palo Alto, California

Phase 3: testing Best Available Therapy (BAT) for Relapsing Multiple Sclerosis

This is a multi-center prospective rater-masked (blinded) randomly assigned controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). you would be randomly assigned at a 1 to 1 (1:1) ratio.

NCT04047628 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

FAQ about this NCT record

Is NCT07159789 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07159789?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07159789?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary